US startup Skribe Medical, which develops wearable cardiac monitoring for cancer care, said on November 10, 2026, that it had raised a US$1.65 million pre-seed round led by SeaX Ventures.

GoAhead Ventures and Marin Sonoma Impact Ventures also participated.

Skribe’s Aurora system combines a multi-sensor adhesive patch with AI analysis to estimate left ventricular ejection fraction, which measures how well the heart pumps blood.

The company said home monitoring was a longer-term goal.

The company said Aurora was selected for the US Food and Drug Administration’s (FDA) READI-Home Innovation Challenge, which aims to reduce readmissions through devices designed for home use.

Skribe added that participation offers early feedback and does not amount to FDA marketing authorization.

Skribe said more than 700 patients had enrolled in its ongoing NOECHO study, which compares its wearable measurements with echocardiography, an established heart imaging method used to monitor cardiac function during cancer therapy.

SeaX helped arrange collaborations with hospitals in Southeast Asia and supported recruitment of more than 100 patients for Skribe’s clinical studies.

🔗 Source: Skribe Medical